Licensing status

Publication and contact information

Assays & screens

Multiplexed detection of proteins in fine-needle aspirates

A method of profiling multiple proteins in fine-needle aspirates could help monitor tumor responses to therapy. Human cancer cells were incubated with a cocktail of 90 antibodies, each tagged with a different nonhuman DNA barcode. Photocleavage and detection of the barcodes provided a readout on the expression of each target protein. In fine-needle aspirates from primary tumors, the method identified treatment-associated changes in tumor protein profiles in four patients who received phosphoinositide 3-kinase (PI3K) inhibitors. Planned work includes using the method to monitor treatment responses in clinical trials of cancer therapies. The DNA barcode detection system used in this study is manufactured by NanoString Technologies Inc.

SciBX 7(5); doi:10.1038/scibx.2014.152
Published online Feb. 6, 2014

Patented by Massachusetts General Hospital; licensed to NanoString Technologies

Ullal, A.V. et al. Sci. Transl. Med.; published online Jan. 15, 2014;
Contact: Ralph Weissleder, Massachusetts General Hospital, Boston, Mass.

Contact: Cesar M. Castro, same affiliation as above